Skip to main content

Day: March 9, 2026

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.htmlMELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed. Key findings include:Tolerability profile supported by dosimetry and low-grade non-hematologic events. Lesion dosimetry indicates no difference in absorbed dose...

Continue reading

Diversified Energy Announces Pricing of Secondary Offering of Common Stock

BIRMINGHAM, Ala., March 09, 2026 (GLOBE NEWSWIRE) — Diversified Energy Company (NYSE: DEC; LSE: DEC) (“Diversified” or the “Company”), today announced the pricing of the previously announced underwritten public offering (the “Secondary Offering”) by certain funds or entities managed by an affiliate of EIG (collectively, the “Selling Stockholder”) of 7,501,585 shares of Diversified’s common stock, par value $0.01 per share (the “common stock”), which represents all remaining holdings of the Selling Stockholder, at a price to the public of $14.45 per share. Subject to the completion of the Secondary Offering, Diversified has agreed to purchase from the underwriter 3,750,000 shares of common stock at a price per share equal to the price per share paid by the underwriter to the Selling Stockholder in the Secondary Offering (the “repurchase”). Diversified...

Continue reading

MAX Power Announces $20 Million Brokered Offering

**NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES** SASKATOON, Saskatchewan, March 09, 2026 (GLOBE NEWSWIRE) — MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FSE: 89N) (“MAX Power” or the “Company”) is pleased to announce a listed issuer financing exemption private placement offering (the “Offering”) for minimum gross proceeds of C$4,000,000 and maximum of up to C$20,000,000. The Offering comprises 15,384,615 units of the Company (each, a “Unit”) at a price of C$1.30 per Unit (the “Issue Price”) and is led by Hampton Securities Limited as the lead agent and sole bookrunner (the “Agent”) on a commercially reasonable efforts basis. Net proceeds will be used for: 1) An ongoing program of analytical testing, resource modeling, and resource estimation of the Lawson Natural Hydrogen...

Continue reading

Arq Reports Fourth Quarter and Full Year 2025 Results

Generated record revenue of approximately $120 million for full-year 2025, driven by PAC performance Reported Adjusted EBITDA(1) of $13 million, representing 26% improvement year-over-year Provided inaugural financial guidance for full-year 2026 Pausing GAC production and development to conduct comprehensive engineering and production process optimization review Announced leadership changes, including appointment of industry veteran as VP Operations and Finance team reorganization GREENWOOD VILLAGE, Colo., March 09, 2026 (GLOBE NEWSWIRE) — Arq, Inc. (NASDAQ: ARQ) (the “Company” or “Arq”), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced its financial and operating results for the quarter and year ended December 31,...

Continue reading

MegaWatt Announces Proposed Consolidation of Shares

Vancouver, British Columbia, March 09, 2026 (GLOBE NEWSWIRE) — MegaWatt Lithium and Battery Metals Corp. (CSE:MEGA) (FSE: WR20) (OTCQB: WALRF) (the “Company“, “MegaWatt Metals” or “MegaWatt”) announces that, at the annual general meeting of shareholders of the Company held on February 19, 2026, the shareholders approved, among other things, the consolidation of the common shares in the capital of the Company (the “Shares”) on the basis of one (1) post‑consolidation Share for a minimum of ten (10) pre-consolidation Shares, with the exact consolidation ratio to be determined by the board of directors of the Company. The Company intends to consolidate the Shares on the basis of one (1) post-consolidation Share for every twelve (12) pre-consolidation Shares (the “Consolidation”). The Company currently has 37,250,400...

Continue reading

Grupo Aeroportuario del Pacifico Announces Annual Ordinary General Shareholder’s Meeting

GUADALAJARA, Mexico, March 09, 2026 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces the following: Pursuant to a resolution adopted by the Board of Directors at its meeting held on February 23, 2026, and in accordance with Articles 180, 181 and other applicable articles of the Mexican General Corporations Law, as well as Article Thirty-Fifth of the Company’s bylaws, GAP invite its shareholders to the Annual Ordinary General Shareholders’ Meeting, to be held at 12:00 p.m. on April 22, 2026, at Midtown Ballroom 3, 3rd floor of the Hilton Midtown Hotel, located at Av. López Mateos 2405-300, Col. Italia Providencia, C.P. 44648, Guadalajara, Jalisco, Mexico, in accordance with the following: ANNUAL ORDINARY GENERAL SHAREHOLDERS’ MEETINGMEETING AGENDAIn compliance...

Continue reading

Itafos to Present at the Sidoti Small Cap Conference

HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) (“Itafos” or “the Company”) announced today that it will be presenting at the Sidoti Small Cap Conference at 3:15 EST on Thursday March 19, 2026. Register here to attend the virtual event: https://sidoti.zoom.us/webinar/register/WN_YCIRIrUhQBuEB2r6HTcp5A. About Itafos Itafos is a phosphate and specialty fertilizer company with businesses and projects spanning three continents:Conda – a vertically integrated phosphate fertilizer business located in Idaho, US, with the following production capacity:approximately 550kt per year of MAP, MAP+, SPA, merchant grade phosphoric acid (“MGA”) and APP approximately 27kt per year of hydrofluorosilicic acid (“HFSA”)Arraias – a vertically integrated phosphate fertilizer business located in Tocantins, Brazil,...

Continue reading

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus fulvestrant by 76% and 67%, respectivelyMINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in the Journal of Clinical Oncology. The cohort consists of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) PIK3CA WT advanced breast cancer (“ABC”), following...

Continue reading

Novonesis named a Great Employer to Work For in North Carolina

Employee PhotoNovonesis employees gathered at the Franklinton, North Carolina site during Manufacturing Day 2025.Franklinton, North Carolina, March 09, 2026 (GLOBE NEWSWIRE) — Novonesis, a global leader in biosolutions, has been named a 2026 Great Employer to Work for in North Carolina by Best Companies Group (BCG), marking the company’s first time earning this prestigious recognition. BCG is a trusted leader in workplace culture research and recognition, distinguishing top companies around the United States for more than 20 years. The honor is based entirely on confidential employee feedback and a comprehensive evaluation of workplace practices, culture, and leadership.  Novonesis ranked 6th on the list of Great Employers to Work for in North Carolina. With more than 700 employees across North Carolina, Novonesis’ recognition...

Continue reading

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast InformationEvent: Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference CallDate: Thursday, March 19, 2026Time: 10:00 a.m. ETConference Call: 1-888-222-5806 (U.S.)1-412-902-6516 (international)Webcast: Webcast...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.